ANI PHARMACEUTICALS, INC Total Liabilities
ANI PHARMACEUTICALS, INC (ANIP) had Total Liabilities of $896.90 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-07
- 2026-06-30: Liabilities $896.90M.
- 2026-03-31: Liabilities $859.67M.
- 2025-12-31: Liabilities $899.65M.
- 2025-09-30: Liabilities $902.34M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $896.90M 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $859.67M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $899.65M 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $902.34M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $881.39M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $848.96M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $855.94M 10-K · filed 2026-02-27 | $855.17M 10-K · filed 2025-02-28 |
| 2024-09-30 | $856.58M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $440.14M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $437.71M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $446.82M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $435.20M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $424.87M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $425.74M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $421.55M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $402.44M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $414.38M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $398.75M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $412.86M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $279.05M 10-Q · filed 2021-11-01 | |
| 2021-06-30 | $288.24M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $260.13M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $265.49M 10-K · filed 2022-03-15 | |
| 2020-09-30 | $267.48M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $274.05M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $281.06M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $244.00M 10-K · filed 2021-03-11 | |
| 2019-09-30 | $243.65M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $239.25M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $234.68M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $233.34M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $246.98M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $239.07M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $238.38M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $237.38M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $187.67M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $182.67M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $184.93M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $153.22M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $150.55M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $144.22M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $131.41M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $125.18M 10-K · filed 2017-03-02 | |
| 2015-09-30 | $127.38M 10-Q · filed 2015-11-03 | |
| 2015-06-30 | $120.62M 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $121.25M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $119.77M 10-K · filed 2016-02-23 | $123.92M 10-K · filed 2015-02-23 |
| 2013-12-31 | $3.54M 10-K · filed 2015-02-23 | |
| 2013-03-31 | $9.33M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $10.59M 10-Q · filed 2013-05-10 | |
| 2012-09-30 | $10.92M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $16.37M 10-Q · filed 2012-08-01 | |
| 2012-03-31 | $16.58M 10-Q · filed 2012-05-08 | |
| 2011-12-31 | $24.56M 10-K · filed 2013-02-28 | |
| 2011-09-30 | $30.74M 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $31.23M 10-Q · filed 2011-08-05 | |
| 2010-12-31 | $25.62M 8-K · filed 2013-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |